Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996040957 - RECOMBINANT FELINE IMMUNODEFICIENCY VACCINES PRODUCED IN BACULOVIRUS

Publication Number WO/1996/040957
Publication Date 19.12.1996
International Application No. PCT/US1996/009224
International Filing Date 06.06.1996
Chapter 2 Demand Filed 07.01.1997
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/155 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2710/14143
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
14011Baculoviridae
14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
14141Use of virus, viral particle or viral elements as a vector
14143viral genome or elements thereof as genetic vector
C12N 2740/15022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
15011Lentivirus, not HIV, e.g. FIV, SIV
15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • AMERICAN HOME PRODUCTS CORPORATION [US]/[US]
Inventors
  • WASMOEN, Terri
  • CHU, Hsien-Jue
Agents
  • MANDEL, Adley, F.
  • BROWN, Keith, John, Symons
Priority Data
08/481,70007.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RECOMBINANT FELINE IMMUNODEFICIENCY VACCINES PRODUCED IN BACULOVIRUS
(FR) VACCINS RECOMBINANTS CONTRE L'IMMUNODEFICIENCE FELINE PRODUITS DANS UN BACULOVIRUS
Abstract
(EN)
The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that results from FIV infection. The invention provides recombinant proteins produced in a baculovirus expression system having at least one internal gene comprising a DNA sequence that encodes either the entire FIV $i(env) region (ENV-ABC), or a DNA sequence consisting of viral nucleotides 6252-8469 of FIV $i(env) (ENV-AB), a DNA sequence consisting of viral nucleotides 6252-6722 and 8264-9140 of FIV $i(env) (ENV-AC), or immunogenic fragments of any of the foregoing either singly or in combination. By immunogenic fragment is meant any portion of the coding sequence of FIV $i(env) polypeptides that induces a beneficial immune response in cats. In another embodiment, the invention encompasses vaccines that comprise one or more of the baculovirus-expressed recombinant FIV proteins described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.
(FR)
La présente invention se rapporte à la prévention ou à l'atténuation, chez les chats, de la maladie causée par le virus de l'immunodéficience féline (VIF). Par prévention ou atténuation de la maladie, l'on entend le soulagement de divers symptômes, y compris les perturbations du système immunitaire, résultant d'une infection à VIF. Cette invention concerne des protéines de recombinaison produites dans un système d'expression d'un baculovirus présentant au moins un gène interne contenant une séquence d'ADN qui code soit la totalité de la région $i(env) du VIF (ENV-ABC), soit une séquence d'ADN composée des nucléotides viraux 6252-8469 d'$i(env) de VIF (ENV-AB), une séquence d'ADN composée des nucléotides viraux 6252-6722 et 8264-9140 d'$i(env) de VIF (ENV-AC), ou encore les fragments immunogènes de l'une quelconque des séquences précitées, individuellement ou en combinaison. Par fragment immunogène, l'on entend toute partie de la séquence codante des polypeptides $i(env) de VIF qui induit une réponse immune bénéfique chez les chats. Dans un autre mode de réalisation, l'invention concerne des vaccins qui comprennent une ou plusieurs des protéines de VIF de recombinaison exprimées par baculovirus précitées, avec un excipient ou diluant pharmaceutiquement acceptable ou un adjuvant pharmaceutiquement acceptable. Dans un autre aspect, l'invention concerne des procédés visant à prévenir ou à atténuer la maladie causée par le VIF, qui consistent à administrer à un félin nécessitant un tel traitement, les vaccins décrits ci-dessus.
Also published as
Latest bibliographic data on file with the International Bureau